ARCUTIS BIOTHERAPEUTICS, INC. Selling, General and Administrative Expense
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Selling, General and Administrative Expense of $82.14 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-05
- ARCUTIS BIOTHERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2026-06-30 was $82.14M, a 18.75% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2026-03-31 was $74.08M, a 15.74% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2025-12-31 was $78.98M, a 37.10% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2025-09-30 was $62.40M, a 6.10% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. selling, general and administrative expense for fiscal 2025 was $274.55M, a 19.69% increase from fiscal 2024.
- ARCUTIS BIOTHERAPEUTICS, INC. selling, general and administrative expense for fiscal 2024 was $229.39M, a 23.90% increase from fiscal 2023.
- ARCUTIS BIOTHERAPEUTICS, INC. selling, general and administrative expense for fiscal 2023 was $185.15M, a 51.60% increase from fiscal 2022.
- ARCUTIS BIOTHERAPEUTICS, INC. selling, general and administrative expense for fiscal 2022 was $122.12M, a 100.30% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $82.14M 10-Q · filed 2026-08-05 | $156.21M 10-Q · filed 2026-08-05 | $235.19M derived: sum of 3 quarters · filed 2026-08-05 | $297.60M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $74.08M 10-Q · filed 2026-05-06 | $153.05M derived: sum of 2 quarters · filed 2026-05-06 | $215.46M derived: sum of 3 quarters · filed 2026-05-06 | $284.63M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $78.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $141.38M derived: sum of 2 quarters · filed 2026-02-25 | $210.55M derived: sum of 3 quarters · filed 2026-08-05 | $274.55M 10-K · filed 2026-02-25 |
| 2025-09-30 | $62.40M 10-Q · filed 2025-10-28 | $131.57M derived: sum of 2 quarters · filed 2026-08-05 | $195.58M 10-Q · filed 2025-10-28 | $253.18M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $69.17M 10-Q · filed 2026-08-05 | $133.17M 10-Q · filed 2026-08-05 | $190.78M derived: sum of 3 quarters · filed 2026-08-05 | $249.60M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $64.00M 10-Q · filed 2026-05-06 | $121.61M derived: sum of 2 quarters · filed 2026-05-06 | $180.43M derived: sum of 3 quarters · filed 2026-05-06 | $238.60M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $57.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $116.42M derived: sum of 2 quarters · filed 2026-02-25 | $174.60M derived: sum of 3 quarters · filed 2026-02-25 | $229.39M 10-K · filed 2026-02-25 |
| 2024-09-30 | $58.82M 10-Q · filed 2025-10-28 | $116.99M derived: sum of 2 quarters · filed 2025-10-28 | $171.78M 10-Q · filed 2025-10-28 | $220.46M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $58.17M 10-Q · filed 2025-08-06 | $112.97M 10-Q · filed 2025-08-06 | $161.64M derived: sum of 3 quarters · filed 2026-02-25 | $209.24M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $54.79M 10-Q · filed 2025-05-06 | $103.47M derived: sum of 2 quarters · filed 2026-02-25 | $151.06M derived: sum of 3 quarters · filed 2026-02-25 | $197.02M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $48.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $96.27M derived: sum of 2 quarters · filed 2026-02-25 | $142.23M derived: sum of 3 quarters · filed 2026-02-25 | $185.15M 10-K · filed 2026-02-25 |
| 2023-09-30 | $47.59M 10-Q · filed 2024-11-06 | $93.55M derived: sum of 2 quarters · filed 2024-11-06 | $136.47M 10-Q · filed 2024-11-06 | $173.49M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $45.96M 10-Q · filed 2024-08-14 | $88.88M 10-Q · filed 2024-08-14 | $125.90M derived: sum of 3 quarters · filed 2025-02-25 | $161.37M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $42.92M 10-Q · filed 2024-05-14 | $79.94M derived: sum of 2 quarters · filed 2025-02-25 | $115.41M derived: sum of 3 quarters · filed 2025-02-25 | $143.04M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $37.02M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $72.50M derived: sum of 2 quarters · filed 2025-02-25 | $100.12M derived: sum of 3 quarters · filed 2025-02-25 | $122.12M 10-K · filed 2025-02-25 |
| 2022-09-30 | $35.47M 10-Q · filed 2023-11-03 | $63.09M derived: sum of 2 quarters · filed 2023-11-03 | $85.10M 10-Q · filed 2023-11-03 | $103.83M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $27.62M 10-Q · filed 2023-08-08 | $49.63M 10-Q · filed 2023-08-08 | $68.36M derived: sum of 3 quarters · filed 2024-02-27 | $84.83M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $22.01M 10-Q · filed 2023-05-09 | $40.73M derived: sum of 2 quarters · filed 2024-02-27 | $57.21M derived: sum of 3 quarters · filed 2024-02-27 | |
| 2021-12-31 | $18.73M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $35.20M derived: sum of 2 quarters · filed 2024-02-27 | $60.97M 10-K · filed 2024-02-27 | |
| 2021-09-30 | $16.47M 10-Q · filed 2022-11-08 | $42.24M 10-Q · filed 2022-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |